Join us in Basel for this exciting ESOC. Be the first to see the main results of many important trials including SWITCH Trial ! There will be also important secondary analysis of RCTs including the clinical importance of haematoma expansion and thrombotic events in #ANNEXA-I

Astounding. I dare say better than TICI 3

The #TASTE #trial supports the use of #Tenecteplase for acute ischemic #stroke <4.5h Though neutral in the intention-to-treat analysis, non-inferiority demonstrated in the per-protocol analysis. Now @ #ESOC2024 👇 European Stroke Org #voiceofstroke

#TRACE3 RCT: TNK (0.25mg/kg) vs BMT for stroke patients between 4.5 - 24h without access to EVT. TNK improved excellent outcome at 90d (RR 1.4 🙌) with no signif. increase in sICH rates ❌️ TNK seemed beneficial across all subgroups #VoiceOfStroke Stroke Trials Stroke: Vascular and Interventional Neurology

Many thanks to Alastair Webb for a fascinating comprehensive talk on #brainhealth and beyond at the Stroke Research Center Bern cluster meeting. The team and prominent international visitors from NZ and Ecuador enjoyed your insights 🙏🇳🇿🇪🇨 Teddy Wu David Seiffge Thomas Meinel Urs Martin Fischer

It was a pleasure having long-time collaborator and friend Teddy Wu for a few days with us in Stroke Research Center Bern Insel Gruppe ! We learned a lot about differences and similarities of stroke management in 🇨🇭 and 🇳🇿 ! Thanks a lot! European Stroke Master Urs Martin Fischer Thomas Meinel

Stephan A Mayer Hooman Kamel We did it 3 times this week; 3hours after last intake of 5mg of Apixaban - no bleeding and discharged home on day 3. Teddy Wu witnessed it. To convince the sceptics, we run DO-IT Trial with Thomas Meinel Urs Martin Fischer Stroke Research Center Bern Luciana Catanese, MD Ashkan Shoamanesh Aristeidis Katsanos

Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle? - The Lancet Neurology thelancet.com/journals/laneu…

Hyvää Juhannusta!! To all the Finns in the world!

We report differences in #stroke outcomes in #TNK vs. #alteplase stratified by ethnicity. In Asian cohorts, TNK had higher recanalization rates. Caucasian cohorts had lower mortality and higher rates of mRS 0-2. Teddy Wu leonard yeo Ching-Hui SIA JHKoh Associate Prof William KF Kong 江国辉副教授

Is Hoover's sign only useful in functional neurological disorders? NOPE. Wonderful experience teaching University of Florida Neurology Residency as the attending this past week. Hoover's can be extremely helpful in the emergency room evaluation of a person with lower extremity weakness. At its core it is a

Really enjoyed the debate on IVT in DOAC patients with my friend & colleague David Seiffge More data is needed to support the use of IVT in patients with concomitant DOAC use. While an RCT would be ideal, a single arm safety study may be the best route for the reasons below:

The first New Zealand team to win a Test series in India 🏏 #INDvNZ #CricketNation

Christmas just arrived..

Great to see our review on intracerebral haemorrhage now published in Nat Rev Neurology ! Great collaboration with Simon Fandler-Höfler Martina Göldlin #YangDu #WilmarJolink #CatharinaKlijn and #DavidWerring! UCL Stroke Research Stroke Research Center Bern European Stroke Master European Stroke Org World Stroke Academy nature.com/articles/s4158…

Teddy Wu Thanks to our amazing prehospital team and ED nurses, too!

LAAO and stroke: We summarize current evidence & ongoing trials: promising option for AF patients to avoid OAC (i.e. after ICH, CAA) or if DOAC alone is not enough (i.e. after #breakthroughstroke) Alexander Benz ⁦ELAPSE⁩ ⁦Stroke AHA/ASA⁩ ahajournals.org/doi/10.1161/ST…

Our study in International Journal of Stroke shows young adults face significant stroke recurrence risks: 4.5-7.3% recurrence rate within just 1 year, increasing to 10.5-12.8% at 5 years and 14.0-20.3% beyond 10 years. Teddy Wu leonard yeo Ching-Hui SIA #YoungStroke doi.org/10.1177/174749…